Specialized Medical Company (TADAWUL:4019)
Saudi Arabia · Delayed Price · Currency is SAR 13.30
-0.42 (-3.06%)
Oct 15, 2026, 3:19 PM AST
TADAWUL:4019 Ratios and Metrics
Market cap in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,325 | 4,510 | - | - | - | - | |
Market Cap Growth | -32.11% | - | - | - | - | - |
Enterprise Value | 4,084 | 5,124 | - | - | - | - |
Last Close Price | 13.30 | 16.92 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.96 | 16.94 | - | - | - | - |
Forward PE | 12.99 | 14.35 | - | - | - | - |
PS Ratio | 2.11 | 2.93 | - | - | - | - |
PB Ratio | 3.38 | 3.80 | - | - | - | - |
P/TBV Ratio | 3.38 | 3.80 | - | - | - | - |
P/FCF Ratio | 10.48 | 19.76 | - | - | - | - |
P/OCF Ratio | 8.32 | 13.97 | - | - | - | - |
PEG Ratio | 1.36 | 0.80 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.60 | 3.33 | - | - | - | - |
EV/EBITDA Ratio | 12.03 | 17.23 | - | - | - | - |
EV/EBIT Ratio | 16.85 | 21.81 | - | - | - | - |
EV/FCF Ratio | 12.87 | 22.45 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.91 | 0.70 | 1.04 | 1.02 | 1.11 | 1.24 |
Debt / EBITDA Ratio | 2.63 | 2.52 | 2.71 | 2.85 | 3.52 | 4.93 |
Debt / FCF Ratio | 2.81 | 3.62 | 2.98 | 5.37 | 6.99 | - |
Net Debt / Equity Ratio | 0.77 | 0.49 | 0.93 | 0.96 | 1.08 | 1.22 |
Net Debt / EBITDA Ratio | 2.47 | 1.94 | 2.67 | 2.98 | 3.92 | 5.91 |
Net Debt / FCF Ratio | 2.39 | 2.53 | 2.66 | 5.07 | 6.80 | -5.25 |
Asset Turnover | 0.68 | 0.69 | 0.70 | 0.69 | 0.65 | 0.61 |
Inventory Turnover | 36.99 | 46.35 | 44.21 | 44.30 | 47.31 | 38.29 |
Quick Ratio | 0.90 | 1.30 | 0.67 | 0.79 | 0.70 | 0.66 |
Current Ratio | 1.01 | 1.42 | 0.76 | 0.87 | 0.76 | 1.12 |
Return on Equity (ROE) | 28.15% | 26.42% | 22.15% | 21.40% | 14.54% | 8.29% |
Return on Assets (ROA) | 6.56% | 6.61% | 7.00% | 6.77% | 4.29% | 2.50% |
Return on Invested Capital (ROIC) | 13.67% | 13.66% | 13.54% | 13.02% | 8.06% | 4.66% |
Return on Capital Employed (ROCE) | 15.10% | 12.70% | 18.10% | 15.70% | 10.30% | 5.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.36% | 5.90% | - | - | - | - |
FCF Yield | 9.54% | 5.06% | - | - | - | - |
Dividend Yield | 2.41% | 1.77% | - | - | - | - |
Payout Ratio | 100.74% | - | 107.98% | 35.57% | 48.56% | 62.54% |
Buyback Yield / Dilution | - | - | -194.12% | - | - | - |
Total Shareholder Return | 2.41% | 1.77% | -194.12% | - | - | - |